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ABSTRACT 
Objective: To date, film-forming systems have been intensively investigated for transdermal drug delivery. Film-forming systems offers various 
advantages compared over conventional transdermal drug delivery systems. The objective of the present study was to study the effect of polymeric 
blend on ex-vivo permeation studies of topical film-forming gel of aceclofenac.  
Methods: Film-forming gels were prepared by using Hydroxypropyl methylcellulose and Eudragit polymeric blend in varied concentrations, 
polyethylene glycol 400 as plasticizer, ethanol as solvent and tween 80 as a penetration enhancer. The prepared film-forming gels were evaluated 
and the influence of the concentration and ratio of polymeric blends used plasticizer and ethanol were investigated.  
Results: All the prepared film-forming gels showed satisfactory properties regarding homogeneity, compatibility, viscosity and pH value. Variation 
in the concentration of polymers showed a variable effect on drug permeation rate from film-forming gels. Almost, all formulations permeated up to 
80% of drug in 12 h and formulation F1 showed a maximum release about 97.54 % in 12 h.  
Conclusion: Film-forming gels of aceclofenac with sustained-release profile were successfully developed and may provide a promising effective 
formulation which may improve patient compliance.  
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INTRODUCTION 
Rheumatoid arthritis is an autoimmune disease in which there is 
joint inflammation, synovial proliferation and destruction of 
articular cartilage. It is a chronic progressive, crippling disorder [1]. 
Arthritis of joints involves inflammation of the synovial membrane, 
Joints become swollen, tender and warm, stiffness limits their 
movement and found in small joints of hands, feet, cervical spine. 
Usually, this disease occurs at the joints, where applied medicament 
is wiped off, due to clothes or any other reason. Thus, there is a need 
to develop to novel drug delivery system which is in a gel form in a 
tube or container, but when applied to skin surface converts or 
transform into a film. Initially, gels provide a drug release and after 
transformation into film prolonged drug release was maintained. 
This concept is helpful for patients suffering from Rheumatoid 
Arthritis where sustained action is required as the frequency of 
administration is more [2]. 
Non-Steroidal Anti-inflammatory drugs (NSAIDS) are used first, 
which provide symptomatic relief (pain, swelling, morning stiffness, 
immobility). Non-steroidal anti-inflammatory drugs such as 
aceclofenac have been widely used in the treatment of rheumatoid 
arthritis, osteoarthritis and musculoskeletal disorders. In oral 
administration of Non-Steroidal Anti-Inflammatory Drugs, tablets 
and capsules led to peptic ulceration anorexia. Other side effects 
such as headache, giddiness, and blurring of vision may take place 
[3]. 
To date, film-forming systems (FFS) have been intensively 
investigated for transdermal drug delivery [4]. The FFS are the semi-
solid system containing film-forming agents along with the drug that 
forms film in-situ after solvent evaporation. They either act as a 
sustained drug release polymeric matrix or as a solvent film that can 
rapidly absorb within the skin. Compared to conventional 
topical/transdermal drug delivery systems, FFS offers various 
benefits, such as non-greasy, transparency, resistant to wipe off, 
longer residence at the site of application, low skin irritation, ease of 
dosage adjustment and greater patient compliance [5]. The studies 
conducted to date have shown promising results, however, further 
studies are needed to establish FFS as an effective drug delivery 
carrier for transdermal application. In the present investigation, 
film-forming systems were developed and evaluated for effective 
transdermal delivery of Aceclofenac (ACF). 
MATERIALS AND METHODS 
Materials 
Aceclofenac was gifted from Shiva Biogenetic Pharmaceuticals Pvt. 
Ltd., Solan India. Eudragit RL 100 was procured from Evonik, 
Germany, India. Polyethylene Glycol (PEG-400) and Hydroxypropyl 
Methyl Cellulose (HPMC) were purchased from SD fine chemicals 
Ltd., India. Ethanol (99% purity) was purchased from Merck, 
Germany. All other chemicals used in the experiments were of 
analytical grade. 
Methods 
Development of film-forming system 
The polymeric solution of eudragit was prepared by dispersion 
method using ethanol as solvent. HPMC was sprinkled over 10 ml of 
ethanol separately. Both solutions were allowed to swell for 24 h to 
produce clear solutions. The polymeric solutions were mixed 
properly with continuous stirring. The ACF drug was dissolved in a 
specified quantity of ethanol. Solvent ethanol is used as it is capable 
of dissolving the drug and is rapidly evaporated after topical 
evaporation leaving a film on the skin. The drug and polymeric 
dispersion were mixed properly with continuous stirring. Finally, 
tween 80, Polyethylene glycol was added to it and volume was made 
up to the mark using ethanol and stirring it until a smooth gel is 
obtained. The speed of stirrer was maintained in the range of 500-
1000 rpm. During the formulation, development care should be 
taken to avoid air bubbles formation [20]. The formulation chart is 
shown in table 1. 
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Table 1: Formulation design of aceclofenac-loaded film-forming gel 
Formulation code ACF (%) HPMC (%) Eudragit RL100 (%) PEG400 (%) Tween 80 (%) Ethanol 
F1 1 1 0.4 3 0.5 q. s  
F2 1 2 0.4 3 0.5 q. s 
F3 1 3 0.4 3 0.5 q. s 
F4 1 1 0.6 3 0.5 q. s 
F5 1 2 0.6 3 0.5 q. s 
F6 1 3 0.6 3 0.5 q. s 
F7 1 1 0.8 3 0.5 q. s 
F8 1 2 0.8 3 0.5 q. s 




Drug-excipient interaction was evaluated using FT-IR spectroscopy 
[4]. IR spectrum of the drug and its combinations with other 
excipients were recorded from the Potassium bromide (KBr) 
dispersion method using AX-1 spectrophotometer (Perkin Elmer, 
USA). The film-forming gel samples was dried and crushed so as it 
can be easily combined with KBr (1:1) were recorded over the range 
of 400 to 4000 cm-1 with the resolution of 4 cm-1.  
pH measurements 
The developed films were kept in the purified water (5 ml) for 2 hr 
at room temperature with continuous stirring. The pH of the 
solution was measured by keeping the electrode in contact with the 
surface of the film under a swelling state [6]. The experiment was 
carried out in triplicate (n=3).  
Rheological studies 
The viscosity and the torque of the developed gel formulations were 
measured using a digital Brookfield viscometer LVDV II+model with 
S 64 spindle [7]. The measurement was performed at a controlled 
temperature of 30±2 °C. About 0.5 gm of the developed formulation 
was used for the measurements. The viscosity and torque were 
determined at 20, 50 and 100 rpm. The experiment was carried out 
in triplicate (n=3).  
Drug content 
The gel formulation of 1 gm was taken in a volumetric flask filled 
with 100 ml of PBS (pH 6.8). The volumetric flask filled with drug-
loaded gel along with PBS stirred for 2 hr using a mechanical stirrer 
in order to dissolve the drug from the gel into the solvent. The 
solution was filtered through Whatman filter paper. The absorbance 
was recorded by UV Vis spectrophotometer at 275 nm after suitable 
dilutions [8].  
Homogeneity 
The developed gel formulations were placed on the petri dish and 
allowed to set into it. These formulations were evaluated for their 
appearance and any possible aggregates via visual inspection. 
Ex-vivo skin permeation study of film-forming gel 
Ex-vivo skin permeation study was carried out as per the method 
described in the literature [9]. The experimental procedures and 
protocols were reviewed and approved by the Institutional Animal 
Ethical Committee (IAEC) [CPCSEA/IAEC/SBS/2017-18/009] Sardar 
Bhagwan Singh Post Graduate Institute of Biomedical Sciences and 
Research, Balawala, Dehradun. The animals were housed in 
standard polypropylene cages and maintained under controlled 
room temperature (22±2 °C) and relative humidity (55±5%) with 
12:12 hour light and dark cycle. The animals were provided with 
commercially available rat normal pellet diet and water ad libitum. A 
section of the young rat skin (3 × 3 mm) from the abdominal region 
of the rat was carefully excised after animal sacrifice. The hairs on 
the skin were removed with the help of scissors and any undesirable 
matter was wiped-out with the help of cotton. The cleaned skin was 
then washed with saline before the experiment. Ex-vivo skin 
permeation of ACF-loaded film forming gels F1-F9 was investigated 
at predetermined time points 0,0.5,1,2,4,6,8,10 and 12 h using 
Franz-diffusion cell. The abdominal skin was washed with PBS (pH 
6.8) and mounted over the diffusion cell. About 1 gm of the gel was 
placed on the donor compartment and covered with aluminium foil 
to prevent drying out of the gel. The temperature of the cell was 
maintained at 37±5 ⁰C and the medium was by magnetic stirrer at 
100 rpm [10]. 
Sample (2 ml) were collected from the receptor compartment at a 
predetermined time interval and then immediately analyzed 
spectrophotometrically at 275 nm against a blank prepared with the 
permeated formulation without the drug. At each sampling time 
point, the medium of the receptor compartment was replaced by the 
equal volume of fresh medium. The experiment was carried out in 
triplicate (n=3). Graph was plotted between the cumulative amount 
of drug permeated in receptor compartment versus time.[21].  
RESULTS AND DISCUSSION 
Formulation development 
The ACF-loaded film-forming gels (F1-F9) were developed using 
variable composition of gelling and film-forming agents (table I). To 
enhance the solubility of the drug and its penetration through the 
skin, PEG and Tween 80 were added in the formulation. The 
developed formulations were evaluated for various physicochemical 
parameters. 
Compatibility studies 
FTIR spectrum of the drug ACF was recorded over the range of 400 
to 4000 cm-1 with the resolution of 4 cm-1 (fig. 1). The peak at 3318 
cm-1 represents–NH Stretching related to broad secondary amine 
and carboxylic acid (hydroxyl) band in ACF. Peak at (1716.8 cm-1) 
represents-C=O Stretching of ketone band. Peak at (1589.5 cm-1) 
represents the C=C bending of the aromatic group. Peak at (1500 cm-
1) represents C-C bending of the aromatic group. Peak at (1480.61 
cm-1) represents the C=C bending of the aromatic group. Peak at 
(1178.86 cm-1) represents C-O stretching of carboxylic acid in ACF. 
FTIR spectrum of the drug ACF and HPMC was recorded over the 
range of 400 to 4000 cm-1 with a resolution of 4 cm-1 (fig. 2). The 
mixture showed the characteristic peaks of ACF and HPMC. The 
broad peak (3371.62 cm-1) represents–NH Stretching related to 
broad secondary amine and carboxylic acid (hydroxyl) band in ACF. 
Peak at (1067.58 cm-1) represents-C-O stretching which is 
characteristic of glucose ring present in HPMC. Peak at (1642 cm-1) 
represents–C=O stretching of carboxylic in ACF. Peak at (1387 cm-1) 
represents C-OH bending in ACF and peak at (1216 cm-1) depicts C-N 
stretching. As per the FTIR spectrum of ACF and HPMC, the mixture 
showed compatibility and their suitability for the formulation 
development. 
FTIR spectrum of the drug ACF and Eudragit was recorded over the 
range of 400 to 4000 cm-1 with the resolution of 4 cm-1 (fig. 3). The 
mixture showed the characteristic peaks of ACF and eudragit. The 
broad peak (3368 cm-1) represents–NH Stretching related to broad 
secondary amine and carboxylic acid (hydroxyl) band in ACF. Peak 
at (2923 cm-1) represents-CH stretching of alkane group present in 
eudragit. Peak at (1644.37 cm-1) represents–C=O stretching of 
carboxylic in ACF. Peak at (1387 cm-1) represents C-OH bending in 
ACF and peak at (770 cm-1) depicts C-Cl stretching. As per the FTIR 
spectrum of ACF and eudragit, the mixture showed compatibility 
and their suitability for the formulation development. 
Kumar et al. 
Int J App Pharm, Vol 13, Issue 4, 2021, 117-122 
119 
 
Fig. 1: FTIR spectrum of ACF recorded over the range of 400 to 4000 cm-1 with the resolution of 4 cm-1 
 
 
Fig. 2: FTIR spectrum of ACF+HPMC recorded over the range of 400 to 4000 cm-1 with the resolution of 4 cm-1 
 
 
Fig. 3: FTIR spectrum of ACF+Eudragit recorded over the range of 400 to 4000 cm-1 with the resolution of 4 cm-1 
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Physical appearance 
Initially, the gel formulation was transparent in nature after 
application. However, it rapidly transformed into opaque with film 
formation. When the film was completely dried, it transformed from 
opaque to transparent.  
pH measurement 
The pH of the gels for transdermal applications should lie within the 
limits of normal skin pH of 4.5-6.8. The pH range deviated from this 
range may cause immunological responses like redness, burning and 
itching of the skin. The prepared film-forming gel formulations F1-
F9 have a pH range of 5.4±0.18 to 6.3±0.08 which is within the pH 
range desired for the skin [11]. 
Viscosity 
The viscosity (cps) and torque (%) of the developed formulations (F1-
F3) was evaluated at 20, 50 and 100 rpm using a digital Brookfield 
viscometer LVDV II+model with S 64 spindle (table 2). Formulations 
F3, F6 and F9 were not evaluated because they were out of the range 
of spindle S 64 maximum capacity of detection (as the spindles of 
higher detection limits were unavailable). The formulation F1 had the 
least viscosity whereas F8 being the most vicious, this increase in 
viscosity can be attributed to the increase in the polymer 
concentration of HPMC as we move down the developed formulations 
within the group. In addition, it was revealed that there was a decrease 
in viscosity with an increase in RPM which represents the resistive 
force offered by the gel to the rotation of the spindle [12]. 
 




RPM 10 Viscosity 
(cps) 
RPM 20 Viscosity 
(cps) 
RPM 50 Viscosity 
(cps) 
RPM 100 Viscosity 
(cps)  % Torque % Torque % Torque % Torque 
F1 0.6 349.9±0.03 1.2 349.9±0.05 2.4 277.9±0.04 4.1 235.9±0.05 
F2 13.7 8118±0.05 18.5 5449±0.04 28.2 2183±0.04 39.7 2281±0.04 
F4 0.6 349.9±0.02 1.2 349.9±0.04 2.6 311.9±0.02 4.4 253.9±0.03 
F5 26.2 13217±0.03 27.8 8238±0.02 35.2 4189±0.04 40 2299±0.02 
F7 0.7 409.9±0.04 1.1 319.9±0.03 1.9 218±0.05 37.5 158±0.05 
F8 26.1 13961±0.02 31.9 9438±0.02 37.5 4399±0.03 41 2359±0.04 
 Note: All data are presented as mean value±SD and n=3 
 
Table 3: Drug content of the film-forming systems 
Drug content of formulations 
Formulation no. F1 F2 F3 F4 F5 F6 F7 F8 F9 


















Note: All data are presented as mean value±SD and n=3 
 
Drug content 
The drug content of the developed formulations was found in the 
range of 98.76±0.321-99.83% (table 3). 
Homogeneity 
The developed formulations in a gel form were evaluated for their 
homogeneity. All the developed film-forming systems (F1-F9) were 
found homogeneous without any grittiness. This ensures a smooth 
application of the formulation which avoids any possible abrasion 
on the skin [13].  
Ex-vivo skin permeation study  
The developed formulations were evaluated for their ability to 
permeate the drug efficiently through the skin in a sustained 
manner. In addition to the control release property, the eudragit 
also acts as a film-forming agent for topical formulations. In 
addition, Tween 80 increases the solubility of the hydrophobic 
drug and enhances the permeation of the drug through the skin. It 
can be easily seen from the results that came from ex-vivo 
permeation studies that with an increase in the polymer 
concentration the release increases. 
 
 
Fig. 4: Percent drug permeation of film-forming systems (F1-F5) (mean±SD and n=3) 
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Fig. 5: Percent drug permeation of film-forming systems (F6-F9) (mean±SD and n=3) 
 
The ex-vivo permeation study showed that the developed formulations 
showed a sustained release effect depending upon the concentration 
of the polymers [16, 17]. It can be seen from the permeation study that 
with an increase in the concentration of HPMC and Eudragit, the 
loaded ACF releases from the polymer matrix at the slower rate as 
shown in fig. 4 and fig. 5. The formulations F7, F8 and F9, due to high 
polymeric concentration showed large sustained drug release effect 
compared to the formulations F1-F6. 
CONCLUSION  
Diseases, such as rheumatoid arthritis usually occurs in joints where 
there is a great possibility exists that the applied dosage form can 
easily wipe off following its topical application. Therefore, we 
developed film-forming systems that have an ability to be there for a 
longer time period. The present investigation showed that the 
developed ACF-loaded film-forming gels have acceptable 
physicochemical properties for the topical application. After the 
topical application, the gel form converts into a thin film which 
releases the drug in a sustained manner. The FTIR studies showed 
compatibility between the drug and the excipients and their suitability 
for the formulation development. Ex vivo permeation studies showed 
the sustained release properties of the developed formulation. To 
conclude, film-forming systems have a great potential for the 
management of various diseases. However, a further in-depth 
investigation is warranted to transform this formulation into a 
successfully marketed product for human application. 
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